Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Front Cardiovasc Med ; 9: 931943, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35958398

RESUMO

Introduction: The incidence of preeclampsia (PE) is about 2-8%, making it one of the leading causes of perinatal morbidity and maternal mortality in the world. Early prophylactic low dose administration (150 mg) of acetylsalicylic acid is associated with a significant reduction in the incidence of early-onset PE, intrauterine growth restriction (IUGR), and neonatal mean stay in the intensive care unit (ICU). Universal implementation of a first-trimester screening system including angiogenic and antiangiogenic markers [the Placental Growth Factor (PlGF) and/or soluble fms-like Tyrosine Kinase-1 (sFlt-1)] has shown a prediction rate of 90% for early-onset PE but entails a high financial cost. The aim of this study is to determine the predictive and preventive capacity of a universal PE first-trimester two-step sequential screening model, determining the PlGF only in patients previously classified as intermediate risk by means of a multivariate model based on resources already used in the standard pregnancy control, in a real clinical setting. We hypothesize that this screening model will achieve similar diagnostic performance as the universal determination of PlGF but at a lower economic cost. Methods and Analysis: This is a prospective, multicentric, cohort study in a real-world clinical setting. Every singleton pregnancy will be recruited at the routine first pregnancy visit. In a first step, the first-trimester risk of PE will be calculated using a multivariate Gaussian distribution model, based on medical history, mean blood pressure, Pregnancy-Associated Plasma Protein A (PAPP-A), and Uterine Artery Doppler Pulsatility Index (UTPI). Patients will be classified into three risk groups for PE: (1) risk ≥ 1/50, high-risk with no further testing (blinded PlGF); (2) risk between 1/51 and 1/500, medium-risk requiring further testing; and (3) risk ≤ 1/501, low-risk with no further testing. In a second step, the PlGF will only be determined in those patients classified as intermediate risk after this first step, and then reclassified into high- or low-risk groups. Prophylactic administration of aspirin (150 mg/day) will be prescribed only in high risk patients. As a secondary objective, sFlt-1 values will be blindly determined in patients with high and intermediate risk to assess its potential performance in the screening for PE. Ethics and Dissemination: The study will be conducted in accordance with the principles of Good Clinical Practice. This study is approved by the Aragon Research Ethics Committee (CEICA) on 3 July 2020 (15/2020). Clinical Trial Registration: ClinicalTrials.gov, identifier: NCT04767438.

2.
Cureus ; 13(7): e16437, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-34422469

RESUMO

Uterine primitive neuroectodermal tumors (PNETs) are rare entities, with only around 70 cases published in the literature. Most of them are diagnosed in advanced stages with rapid progression and poor prognosis. Herein, we present a case of a 71-year-old patient with postmenopausal metrorrhagia and an ultrasound finding of endometrial thickening. The pathological diagnosis after an endometrial biopsy showed PNET. In the study of extension, possible distant dissemination with infiltration of the sigmoid and liver was observed. Chemotherapy treatment was proposed, but not begun due to the rapid progression of the disease. Four months after the initial diagnosis, the patient died of multiple organ failure. While there is no optimal chemotherapy treatment regimen for PNET, some studies have reported encouraging results. It is necessary to publish more studies emphasizing the follow-up and survival of the disease to establish which may be the best treatment option and thus improve the current poor prognosis.

3.
Eur. j. anat ; 20(4): 371-376, oct. 2016. ilus
Artigo em Inglês | IBECS | ID: ibc-157771

RESUMO

Atrophy of the corpus callosum among alcoholics was classically restricted to patients affected by Marchiafava-Bignami (MB) disease. It was further observed in patients with thiamine and/or niacin deficiency, or in alcoholics who had consumed alcoholic beverages for a long period. A 42-year-old alcoholic patient was admitted with a full-blown alcohol withdrawal syndrome. After recovery, unstable gait and marked pyramidal signs were observed. A brain magnetic resonance was performed, which revealed corpus callosum atrophy. At discharge the patient was placed under ambulatory care. Nevertheless, he never attended his appointments and he was readmitted several times with withdrawal syndrome. Repeated MRI studies showed no remarkable changes besides progressive atrophy of the corpus callosum. Indeed, the area of corpus callosum was markedly reduced when compared with that of 20 alcoholics and 5 further patients with Wernicke´s encephalopathy. Therefore, the clinical picture is consistent with classic MB disease, and the more severe atrophy than that observed in the remaining alcoholics suggests that additional mechanisms may play a role in MB disease


No disponible


Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Corpo Caloso/fisiopatologia , Atrofia/etiologia , Alcoolismo/complicações , Transtornos Induzidos por Álcool/diagnóstico , Doença de Marchiafava-Bignami/diagnóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...